Preoperative Combination of Pembrolizumab and Radiation Therapy in Patients With Operable Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Antineoplastics
Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms PEARL

18 Apr 2024 Planned primary completion date changed from 21 Feb 2022 to 3 Dec 2024.
23 Sep 2023 Primary endpoint (Number of Patients Who do Not Necessitate a Delay in Standard of Care Treatment After Receiving the Investigational Combination of Preoperative Pembrolizumab and Radiation) has been met according to results presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference.
23 Sep 2023 Results presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com